Un estudio para evaluar la eficacia, seguridad, farmacocinética y farmacodinámica de ocrelizumab en participantes con esclerosis múltiple recurrente y esclerosis múltiple primaria progresiva
Un estudio multicéntrico, abierto, de un solo brazo para evaluar la eficacia, seguridad, farmacocinética y farmacodinámica de ocrelizumab en pacientes chinos con esclerosis múltiple recurrente y esclerosis múltiple primaria progresiva
The main purpose of this study is to evaluate the efficacy of ocrelizumab in participants with relapsing multiple sclerosis (RMS) and to characterize the ocrelizumab pharmacodynamic (PD) profile in Chinese participants with primary progressive multiple sclerosis (PPMS).
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Tipo de estudio
Tipo de estudio
Inscripción (Estimado)
Inscripción
Fase
Fase
- Fase 4
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Beijing, Porcelana, 100034
- Peking University First Hospital
-
Beijing, Porcelana, 100032
- Peking Union Medical College Hospital
-
Beijing, Porcelana, 100730
- Beijing Hospital of Ministry of Health
-
Changsha, Porcelana, 410008
- Xiangya Hospital Central South University
-
Chengdu, Porcelana, 610041
- West China Hospital of Sichuan University
-
Chongqing, Porcelana, 400016
- The First Affiliated Hospital, Chongqing Medical University
-
Guangzhou, Porcelana, 510080
- The First Affiliated Hospital of Sun Yat-sen University
-
Guangzhou, Porcelana, 510630
- The Third Affiliated Hospital of Sun Yat-Sen University
-
Hangzhou, Porcelana, 310003
- The First Affiliated Hospital of College of Medicine, Zhejiang University
-
Hohhot, Porcelana, 010011
- Inner Mongolia Autonomous Region People's Hospital
-
Lanzhou, Porcelana, 730030
- Lanzhou University Second Hospital
-
Shenyang, Porcelana, DUMMY_VALUE
- The First Hospital of China Medical University
-
Shijiazhuang, Porcelana, 050000
- The Second Hospital of Hebei Medical University
-
Taiyuan, Porcelana, 030000
- 1st Affiliated Hospital of Shanxi Medical University
-
Wuhan, Porcelana, 430030
- Tongji Hospital Tongji Medical College Huazhong University of Science and Technology
-
Ürümqi, Porcelana, 830000
- Xinjiang People Hospital
-
-
Jiangxi
-
Nanchang, Jiangxi, Porcelana, 330209
- The First Affiliated Hospital of Nanchang University
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Diagnosis of RMS/PPMS in accordance with the revised 2017 McDonald Criteria
- EDSS score from 0-5.5 (RMS) or 3.0-6.5 (PPMS), inclusive, at screening and baseline
- Documented MRI of brain with abnormalities consistent with MS before screening
Exclusion Criteria:
- Diagnosis of PPMS or non-active secondary progressive multiple sclerosis (SPMS) (only for RMS cohort)
- History of relapsing remitting multiple sclerosis (RRMS) or SPMS at screening (only for PPMS cohort)
- Disease duration of more than 10 years in participants with an EDSS ≤ 2.0 at screening (only for RMS cohort)
- History of confirmed or suspected progressive multifocal leukoencephalopathy (PML)
- Inability to complete an MRI scan or contraindication to Gd administration
- Contraindications to mandatory pre-medications (i.e., corticosteroids and antihistamines)
- Known presence of other neurologic disorders if they could interfere with the diagnosis of MS or assessments of efficacy and/or safety during the study
- Any concomitant disease that may require chronic treatment with systemic corticosteroids or immunosuppressants during the course of the study
- Known history of human immunodeficiency virus (HIV) infection
- Lack of peripheral venous access
- Previous treatment with B-cell targeted therapies (i.e., rituximab, ocrelizumab, atacicept, belimumab, or ofatumumab), unless the last infusion was at least 6 months prior to screening
- Positive screening tests for hepatitis B virus (HBV) and/or hepatitis C virus (HCV)
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: No aleatorizado
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Experimental: RMS Cohort
Participants with RMS will receive ocrelizumab, 300 milligrams (mg), intravenous (IV) infusions on Days 1 and 15 of Cycle 1 and thereafter as a single infusion of 600 mg, IV, for all subsequent cycles every 24 weeks (Q24W) (1 Cycle=24 weeks). |
Ocrelizumab will be administered as per the schedule specified in the respective arms.
Otros nombres:
|
|
Experimental: PPMS Cohort
Participants with PPMS will receive ocrelizumab, 300 mg, IV infusions on Days 1 and 15 of Cycle 1 and thereafter as a single infusion of 600 mg, IV, at Week 24 (1 Cycle=24 weeks). |
Ocrelizumab will be administered as per the schedule specified in the respective arms.
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Periodo de tiempo |
|---|---|
|
RMS Cohort: Tasa anualizada de recaídas definidas en el protocolo
Periodo de tiempo: Hasta aproximadamente 1,6 años
|
Hasta aproximadamente 1,6 años
|
|
Cohorte PPMS: Niveles de Células B en Sangre
Periodo de tiempo: Hasta la Semana 48
|
Hasta la Semana 48
|
|
Cohorte de EMPSP: Porcentaje de participantes que alcanzaron niveles de células B de diferenciación de clúster 19 (CD19+) de <10 células/microlitro (μL) en la semana 48
Periodo de tiempo: A la semana 48
|
A la semana 48
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Cohorte RMS: Porcentaje de participantes sin evidencia de actividad de la enfermedad (NEDA3) durante un periodo de 48 semanas
Periodo de tiempo: Hasta la semana 48
|
Hasta la semana 48
|
|
|
Cohorte RMS: Porcentaje de participantes sin recaída a las 48 semanas
Periodo de tiempo: Hasta la semana 48
|
Hasta la semana 48
|
|
|
Cohorte RMS: Porcentaje de participantes que presentan NEDA3 durante un periodo de 24 semanas
Periodo de tiempo: Hasta la semana 24
|
Hasta la semana 24
|
|
|
Cohorte RMS: Número total de lesiones T1 potenciadas con Gadolinio (Gd) detectadas mediante Resonancia Magnética (RM) cerebral
Periodo de tiempo: Hasta la semana 48
|
Hasta la semana 48
|
|
|
Cohorte de RMS: Número total de lesiones nuevas o en aumento de hiperintensidad en T2 detectadas mediante resonancia magnética cerebral
Periodo de tiempo: Hasta la semana 48
|
Hasta la semana 48
|
|
|
Cohortes de RMS y PPMS: Cambio desde el valor basal hasta la semana 48 en la concentración de cadena ligera de neurofilamento sérico (Nfl)
Periodo de tiempo: Desde la línea de base hasta la semana 48
|
Desde la línea de base hasta la semana 48
|
|
|
Cohortes de RMS y EMPS: Concentración sérica de Ocrelizumab
Periodo de tiempo: Hasta la semana 48
|
Hasta la semana 48
|
|
|
Cohorte de RMS: Niveles de células B en sangre
Periodo de tiempo: Hasta la semana 48
|
Hasta la semana 48
|
|
|
Cohorte RMS: Porcentaje de participantes que alcanzan niveles de células B CD19+ de <10 células/μL en la semana 48
Periodo de tiempo: A la semana 48
|
A la semana 48
|
|
|
Cohorte de PPMS: Número total de lesiones realzadas con gadolinio T1 detectadas por resonancia magnética cerebral en la semana 24 y la semana 48
Periodo de tiempo: Semana 24 y Semana 48
|
Semana 24 y Semana 48
|
|
|
Cohorte de PPMS: Número Total de Lesiones T2 Hiperintensas Nuevas o Aumentadas de Tamaño Detectadas por Resonancia Magnética Cerebral en la Semana 24 y la Semana 48
Periodo de tiempo: Semana 24 y Semana 48
|
Semana 24 y Semana 48
|
|
|
Cohortes de EMRE y EMPP: Número de participantes con eventos adversos (EA)
Periodo de tiempo: Hasta aproximadamente 1,8 años
|
Hasta aproximadamente 1,8 años
|
|
|
Cohortes de RMS y PPMS: Cambio respecto al nivel basal de linfocitos T
Periodo de tiempo: Hasta aproximadamente 1,8 años
|
Hasta aproximadamente 1,8 años
|
|
|
RMS and PPMS Cohorts: Change From Baseline to Week 48 in Expanded Disability Status Scale (EDSS)
Periodo de tiempo: Baseline up to Week 48
|
EDSS is a scale for assessing neurologic impairment in participants with multiple sclerosis (MS). EDSS is based on a standard neurological examination, incorporating functional systems (visual, brainstem, pyramidal, cerebellar, sensory, bowel and bladder, and cerebral [or mental]) that are rated and then scored as a functional systems scores (FSS), and ambulation, which is scored as ambulation score. Each FSS is an ordinal clinical rating scale ranging from 0 to 5 or 6 and an ambulation score that is rated from 0 to 16. These ratings are then used in conjunction with observations, as well as information, concerning ambulation and use of assistive devices to determine the total EDSS score. Values are from 0 points (normal neurological examination) up to 10 points (death), increasing in increments of 0.5 points. Higher scores represent increased disability. |
Baseline up to Week 48
|
|
RMS and PPMS Cohorts: Change From Baseline to Week 48 in Timed 25-Foot Walk Test (T25FWT)
Periodo de tiempo: Baseline up to Week 48
|
The T25FWT test is a performance measure used to assess walking speed based on a timed 25-foot walk. The participant is directed to start at one end of a clearly marked 25-foot course and is instructed to walk 25 feet as quickly and safely as possible and immediately walk back the same distance. Score for the T25FWT is the average of the two completed trials. The time taken to complete the test is measured in seconds. The longer it takes to walk, higher the score, which indicates deterioration and greater impairment. Lower times indicate better performance and greater mobility. A 20% change from baseline of the averaged T25FWT is typically considered clinically meaningful. |
Baseline up to Week 48
|
|
RMS and PPMS Cohorts: Change From Baseline to Week 48 in 9-Hole Peg Test (9-HPT)
Periodo de tiempo: Baseline up to Week 48
|
The 9-HPT is a performance measure used to assess upper extremity (arm and hand) function. Participants are instructed to place pegs one by one into each of nine holes arranged in a board stabilized with a plastic nonslip sheet on a solid table, and then to remove these pegs from the holes. Both the dominant and non-dominant hands are tested twice (two consecutive trials for each hand). The participants are required to complete two successful trials for each hand. The amount of time (in seconds) required to place and remove all nine pegs is recorded for each trial. More time indicates higher raw scores, which indicates deterioration. A 20% change from baseline is typically considered clinically meaningful. |
Baseline up to Week 48
|
|
RMS and PPMS Cohorts: Change From Baseline in EuroQoL 5-Dimension Questionnaire (5-Level Version; EQ-5D-5L) Index Score at Week 48
Periodo de tiempo: Baseline, Week 48
|
The EQ-5D-5L is a self-reported health status questionnaire that consists of six questions used to calculate a health utility score for use in health economic analysis. There are two components to the EQ-5D-5L: a five-item health state profile that assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression used to obtain an Index Utility Score, as well as a visual analogue scale (VAS) that measures health state. The VAS is designed to rate the participant's current health state on a scale from 0 to 100, where 0 represents the worst imaginable health state and 100 represents the best imaginable health state. |
Baseline, Week 48
|
|
RMS and PPMS Cohorts: Percentage of Participants With Suicidal Ideation or Behaviour, as Assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS)
Periodo de tiempo: Up to approximately 1.8 years
|
C-SSRS is an assessment tool used to assess lifetime suicidality of participant (at baseline) as well as any new instances of suicidality (C-SSRS since last visit). Structured interview prompts recollection of suicidal ideation, including intensity of ideation, behavior, and attempts with actual/potential lethality. Categories have binary responses (yes/no) and include Wish to be Dead; Non-specific Active Suicidal Thoughts; Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act; Active Suicidal Ideation with Some Intent to Act, without Specific Plan; Active Suicidal Ideation with Specific Plan and Intent, Preparatory Acts and Behavior; Aborted Attempt; Interrupted Attempt; Actual Attempt (non-fatal); Completed Suicide. Suicidal ideation/behavior is indicated by a "yes" answer to any of the listed categories. Score of 0 is assigned if no suicide risk is present. Score of 1 or higher indicate suicidal ideation or behavior. |
Up to approximately 1.8 years
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Investigadores
Investigadores
- Director de estudio: Clinical Trials, Hoffmann-La Roche
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Inicio del estudio
Finalización primaria (Estimado)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Enfermedades del Sistema Nervioso
- Procesos Patológicos
- Enfermedad crónica
- Atributos de la enfermedad
- Enfermedades autoinmunes
- Enfermedades del sistema inmunológico
- Enfermedades Autoinmunes Desmielinizantes, SNC
- Enfermedades Autoinmunes del Sistema Nervioso
- Enfermedades desmielinizantes
- Condiciones Patológicas, Signos y Síntomas
- Esclerosis múltiple
- Esclerosis Múltiple Crónica Progresiva
- ocrelizumab
Otros números de identificación del estudio
Otros números de identificación del estudio
- YN44938
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .